This company has been acquired
Tourmaline Bio Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Sandeep Kulkarni
Chief executive officer
US$848.3k
Total compensation
| CEO salary percentage | 68.97% |
| CEO tenure | no data |
| CEO ownership | 2.9% |
| Management average tenure | 2yrs |
| Board average tenure | 1yr |
Recent management updates
Recent updates
Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action
Sep 09Tourmaline Bio (NASDAQ:TRML) Is In A Good Position To Deliver On Growth Plans
Aug 03
We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate
Apr 19Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
Oct 13Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish
Mar 22Tourmaline Bio: Time For A Pause
Jan 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$88m |
| Mar 31 2025 | n/a | n/a | -US$83m |
| Dec 31 2024 | US$848k | US$585k | -US$73m |
| Sep 30 2024 | n/a | n/a | -US$64m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$3m | US$114k | -US$42m |
Compensation vs Market: Sandeep's total compensation ($USD848.25K) is below average for companies of similar size in the US market ($USD5.44M).
Compensation vs Earnings: Sandeep's compensation has been consistent with company performance over the past year.
CEO
Sandeep Kulkarni (43 yo)
Dr. Sandeep C. Kulkarni, M.D. was Chief Operating Officer of Immunovant, Inc. He serves as Co-Founder, CEO and Director at Tourmaline Bio, Inc. From July to October 2018, he served as Vice President, Speci...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$848.25k | 2.93% $ 36.2m | |
| CFO & Treasurer | 2yrs | US$1.37m | 0.056% $ 689.2k | |
| Chief Business Officer | no data | US$582.25k | 0.27% $ 3.3m | |
| Chief Technology Officer | no data | no data | no data | |
| Vice President of People | no data | no data | no data | |
| Chief Regulatory Officer | no data | US$886.62k | 0.20% $ 2.5m | |
| Senior VP & Head of Quality | no data | no data | no data | |
| Chief Commercial Officer | 2.1yrs | no data | no data | |
| Senior Vice President of Medical Research | no data | no data | no data | |
| VP & TA Head of Ophthalmology | 1.8yrs | no data | no data | |
| VP & Head of Medical Affairs | no data | no data | no data | |
| VP & Head of Pharmacovigilance | no data | no data | no data |
Experienced Management: TRML's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$848.25k | 2.93% $ 36.2m | |
| Independent Director | no data | US$152.33k | 0.0020% $ 24.9k | |
| Independent Chairman | 1.8yrs | US$230.13k | 0% $ 0 | |
| Independent Director | no data | US$154.33k | 3.67% $ 45.5m | |
| Independent Director | no data | US$157.83k | 0.0020% $ 24.9k | |
| Chairman of Cardiovascular Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | no data | US$154.83k | 0.34% $ 4.2m | |
| Member of Cardiovascular Scientific Advisory Board | 1yr | no data | no data | |
| Independent Director | no data | US$145.38k | 0.32% $ 4.0m | |
| Member of Cardiovascular Scientific Advisory Board | 1yr | no data | no data | |
| Member of Cardiovascular Scientific Advisory Board | 1yr | no data | no data | |
| Member of Cardiovascular Scientific Advisory Board | 1yr | no data | no data |
Experienced Board: TRML's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/29 06:29 |
| End of Day Share Price | 2025/10/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tourmaline Bio, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Yatin Suneja | Guggenheim Securities, LLC |